 Home > Active Ingredient News > Study of Nervous System > Alzheimer's & Dementia: Are TNF-α inhibitors more effective than methotrexate in preventing AD?

Alzheimer's & Dementia: Are TNF-α inhibitors more effective than methotrexate in preventing AD?

 Last Update: 2021-09-29
 Source: Internet
 Author: User

Tags

brain tumor images

cytokines inflammation

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Alzheimer's disease (AD) affects nearly 6 million people in the United States and accounts for 60% to 80% of dementia cases
.

There is currently no available treatment that can slow down or prevent the progression of AD or the resulting neuronal damage, dementia, cognitive decline and eventual death

Inflammation is believed to play a key role in the development of AD , so drugs that reduce inflammation can prevent the occurrence of AD or effectively prevent or reverse its progress
.

A mediator of inflammation is the production of tumor necrosis factor (TNF)-α, which is a cytokine with pro-inflammatory and immunomodulatory functions.

Inflammation is believed to play a key role in the development of AD Inflammation is thought to play a key role in the development of AD Prevent immune rheumatoid arthritis

Some existing evidence that big brain levels of TNF-α and pathophysiology and progression of the disease related to AD
.

Therefore, treatment with TNF inhibitors may be effective in preventing and/or reversing the disease process

Great pathophysiology and disease TNF-α levels in the brain of AD progress of the TNF-α levels in the brain of AD pathophysiology and progression of disease-related molecule can not cross the blood-brain barrier molecules can not cross the blood-

In addition, it has been hypothesized that outside the central nervous system, peripheral inhibition of TNF-α may lead to clinical improvements in AD results without crossing the blood-brain barrier, but the current evidence to support this hypothesis is limited
.

Recently, researchers compared the risk of dementia and AD in patients who started using methotrexate and those who started using TNF inhibitors
.

Researchers used insurance claim data from a database of patients eligible for commercial insurance and medical insurance to estimate the risk of dementia and AD in rheumatoid arthritis (RA) patients who started using TNF inhibitors and those who started using methotrexate
.

The sensitivity analysis included all patients who did not require RA diagnosis

diagnosis

Schematic diagram of the research process

Schematic diagram of research process Schematic diagram of research process

In this study, a total of 11092 new TNF inhibitor patients and 44,023 new methotrexate patients were confirmed, with 8925 people in each group being matched
.

Dementia occurred in 1.

In both groups 1.

Started with TNF in patients with methotrexate in patients with inhibitors in dementia or AD no significant differences in risk started TNF in patients with dementia or patients with inhibitor methotrexate AD no significant differences in risk of

Original source:

David M.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.